Three red biotech firms enter finals of BIOTECHNICA Award
Hanover – Addex Pharmaceuticals SA, Apeiron AG and and Galapagos Genomics NV have been chosen as finalists for this year’s European BIOTECHNICA Award. From Switzerland, Austria and Belgium respectively, one of the three firms will take home the honors – and pocket cash prize and the lion’s share of a75,000 in awards. The two other finalists will receive non-cash prizes. The European BIOTECHNICA Award is Europe’s biggest prize for biotech companies. It will be a granted at the opening ceremony of the trade fair on October 4th, the day before it is opened for general activity.
Based in Plan-Les-Ouates near Geneva, Swiss Addex Pharmaceuticals develops agents used in products for treating Parkinson’s disease, schizophrenia, anxiety attacks, depression and disorders affecting the central nervous system. The company is listed on the Swiss Stock Exchange.
Viennese biotech company Apeiron Biologics specialises in the development of enzyme-based biotherapies for treating ARDS (acute respiratory distress syndrome). Recently, the company entered into a lucrative collaboration with pharmaceutical major GlaxoSmithKline.
Galapagos Genomics is a Belgian biotech company based in Mechelen that develops pharmaceutical products for the treatment of bone and joint disease, including bone metastases. The firm also operates a profitable drug discovery service business that has had a record year in terms of sales and earnings.
Naming a winner not an easy task
Professor Peter Stadler, the chairman of the international jury of nine experts whose task it was to select the finalists, said its members “were impressed by the innovative technology developed by all three companies, and are confident that their products and business models hold a lot of promise.” This is the eighth time that Deutsche Messe AG and its partners have organised the competition. The criteria for target companies are quite strict; applicant companies can’t be more than three years old, employ more than 30 people, or have annual turnover exceeding EUR300m. At the same time, their products have to have proven market relevance.